Etoposide, prednisone, vincristina, ciclofosfamide e doxorubicina (DA-EPOCH) con o senza rituximab più erwinia asparaginasi ricombinante (JZP458) per il trattamento della leucemia linfoblastica acuta B Ph negativa o leucemia linfoblastica acuta T di nuova diagnosi
Etoposide, prednisone, vincristina, ciclofosfamide e doxorubicina a dose aggiustata (DA-EPOCH) ± Rituximab + Erwinia asparaginasi ricombinante (JZP458; Rylaze®) per il trattamento di adulti di nuova diagnosi affetti da linfoma/leucemia linfoblastica acuta negativi al cromosoma Philadelphia
This phase II trial tests how well etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin (DA-EPOCH) with or without rituximab plus recombinant Erwinia asparaginase (JZP458) works in treating patients with newly diagnosed Philadelphia chromosome (Ph) negative B-acute lymphoblastic leukemia (ALL) or T-ALL. Chemotherapy drugs, such as etoposide, vincristine, cyclophosphamide and doxorubicin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Anti-inflammatory drugs, such as prednisone, lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. JZP458 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving DA-EPOCH with or without rituximab plus JZP458 may kill more cancer cells in patients with newly diagnosed Ph negative B-ALL or T-ALL.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
- Droga: Cyclophosphamide
- Droga: Prednisone
- Procedura: Biospecimen Collection
- Biologico: Rituximab
- Procedura: Computed Tomography
- Procedura: Positron Emission Tomography
- Biologico: Filgrastim
- Biologico: Pegfilgrastim
- Droga: Asparaginase Erwinia chrysanthemi
- Procedura: Bone Marrow Collection
- Droga: Doxorubicin
- Droga: Etoposide
- Droga: Vincristine
Descrizione dettagliata
OUTLINE:
Patients receive etoposide intravenously (IV), doxorubicin IV and vincristine IV over 96 hours on days 1-4, cyclophosphamide IV over 1 hour on day 5, prednisone orally (PO) twice daily (BID) on days 1-5 of each cycle. In addition, CD20 positive patients receive rituximab IV on day 1 or 5 of each cycle. Patients also receive JZP458 intramuscularly (IM) once every 2-3 days on days 7-21 for up to 7 doses. Cycles repeat every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity. Starting on day 6, 7, or 8, patients also receive pegfilgrastim subcutaneously (SC) once or filgrastim SC once daily (QD) until absolute neutrophil count (ANC) > 2000/uL past nadir. Patients also undergo blood sample collection and bone marrow collection throughout the study. Additionally, patients with extramedullary disease may undergo computed tomography (CT) or positron emission tomography (PET)/CT throughout the study.
After completion of study treatment, patients are followed up every 3 months for 2 years then every 6 months for up to 3 years.
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Fase 2
Contatti e Sedi
Luoghi di studio
-
-
Washington
-
Seattle, Washington, Stati Uniti, 98109
- Fred Hutch/University of Washington Cancer Consortium
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Adults (age 18 years and older) with newly-diagnosed Ph- B-ALL or T-ALL
- In the opinion of the treating investigator, patients must be an unsuitable candidate for a pediatric-inspired regimen, reasons for which may include (but not be limited to) older age (e.g., ≥ 40 years), practical/logistical barriers to or toxicity concerns from administration of a pediatric-inspired regimen
- Marrow or blood involvement by ALL detectable by multi-parameter flow cytometry (MFC)
- Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2. (Performance status of 3 will be allowed if poor performance status is thought to be directly secondary to ALL.)
- Total bilirubin ≤ 2.0 x upper limit of normal (ULN) (unless attributed to Gilbert's disease or other causes of inherited indirect hyperbilirubinemia, at which point total bilirubin must be ≤ 4.0 x ULN) (Note: Patients with liver test abnormalities attributable to hepatic involvement by ALL will be permitted if the total bilirubin is ≤ 5.0 x ULN and alanine aminotransferase [ALT]/aspartate aminotransferase [AST] are ≤ 8.0 x ULN.)
- AST (serum glutamic oxaloacetic transaminase [SGOT])/ALT (serum glutamic pyruvic transaminase [SGPT]) ≤ 5.0 x institutional ULN. (Note: Patients with liver test abnormalities attributable to hepatic involvement by ALL will be permitted if the total bilirubin is ≤ 5.0 x ULN and ALT/AST are ≤ 8.0 x ULN.)
- Calculated creatinine clearance of ≥ 60 ml/min/1.73 m^2, as measured by the Modification of Diet in Renal Disease (MDRD) equation, will be eligible
- As patients with ALL frequently have cytopenias, no hematologic parameters will be required for enrollment or to receive the first cycle of treatment. However, adequate recovery of blood counts will be required to receive subsequent cycles
- Ability to give informed consent and comply with the protocol
- Anticipated survival of at least 3 months, independent of ALL
- Female subjects of childbearing potential should use effective non-hormonal contraceptive methods during treatment with JZP458 and for 3 months after the last dose of study drug. Male subjects with female partners of childbearing potential must agree to use an effective method of birth control from the time of signing the consent form until at least 3 months after the last dose of study drug
Exclusion Criteria:
-
Prior systemic therapy for ALL except to control acute symptoms and/or leukocytosis (e.g., corticosteroids, cytarabine, etc.). Cytarabine 500 mg/m^2 per dose up to 2 doses and/or the equivalent of prednisone 50 mg/m^2/day for up to 2 days are permitted
-
Burkitt lymphoma/leukemia
-
Isolated extramedullary or known parenchymal central nervous system (CNS) disease
-
Known hypersensitivity or intolerance to any of the agents under investigation
-
Known history of grade 3+ pancreatitis or chronic pancreatic insufficiency
-
Known active chronic liver disease including, but not limited to, non-alcoholic steatohepatitis, cirrhosis, or non-alcoholic fatty liver disease
-
Other medical or psychiatric conditions that in the opinion of the investigator would preclude safe participation in the protocol
-
Pregnant or nursing
- Pregnancy test is only required in women, unless they are highly unlikely to conceive (defined as [1] surgically sterilized, or [2] postmenopausal [i.e., a woman who is > 50 years old or who has not had menses for ≥ 1 year], or [3] not heterosexually active)
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: Treatment (DA-EPOCH, rituximab, JZP458)
Patients receive etoposide IV, doxorubicin IV and vincristine IV over 96 hours on days 1-4, cyclophosphamide IV over 1 hour on day 5, prednisone PO BID on days 1-5 of each cycle. In addition, CD20 positive patients receive rituximab IV on day 1 or 5 of each cycle. Patients also receive JZP458 IM every 2-3 days on days 7-21 for up to 7 doses. Cycles repeat every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity. Starting on day 6, 7, or 8, patients also receive pegfilgrastim SC once or filgrastim SC QD until ANC > 2000/uL past nadir. Patients also undergo blood sample collection and bone marrow collection throughout the study. Additionally, patients with extramedullary disease may undergo CT or PET/CT throughout the study. |
Given IV
Altri nomi:
Given PO
Altri nomi:
Undergo blood sample collection
Altri nomi:
Given IV
Altri nomi:
Undergo CT or PET/CT
Altri nomi:
Undergo PET/CT
Altri nomi:
Given SC
Altri nomi:
Given SC
Altri nomi:
Given IM
Altri nomi:
Undergo bone marrow sample collection
Altri nomi:
Given CIV
Altri nomi:
Given CIV
Altri nomi:
Given CIV
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Measurable residual disease (MRD) negativity
Lasso di tempo: After 4 cycles of treatment (cycle length = 21 days)
|
Will be measured by multi-parameter flow cytometry (MFC). Will be assessed according to the National Comprehensive Cancer Network response criteria. |
After 4 cycles of treatment (cycle length = 21 days)
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
MRD negativity
Lasso di tempo: After 1 cycle of study therapy (cycle length = 21 days)
|
Will be measured by MFC. Will be assessed descriptively, using means, medians, and associated confidence intervals for continuous measures, simple ratios and Clopper-Pearson confidence intervals for binary measures. |
After 1 cycle of study therapy (cycle length = 21 days)
|
|
Incidence of grade 3 or higher non-hematologic adverse events (AEs)
Lasso di tempo: Up to 30 days after last dose of study treatment
|
Will be assessed descriptively, using means, medians, and associated confidence intervals for continuous measures, simple ratios and Clopper-Pearson confidence intervals for binary measures. The incidence of AEs will be reported as ratios or percentages. |
Up to 30 days after last dose of study treatment
|
|
Event-free survival (EFS)
Lasso di tempo: Up to 5 years
|
Will be assessed descriptively, using means, medians, and associated confidence intervals for continuous measures, simple ratios and Clopper-Pearson confidence intervals for binary measures. Kaplan-Meier curves will be used to depict EFS. |
Up to 5 years
|
|
Relapse-free survival (RFS)
Lasso di tempo: Up to 5 years
|
Will be assessed descriptively, using means, medians, and associated confidence intervals for continuous measures, simple ratios and Clopper-Pearson confidence intervals for binary measures. Kaplan-Meier curves will be used to depict RFS. |
Up to 5 years
|
|
Overall survival (OS)
Lasso di tempo: Up to 5 years
|
Will be assessed descriptively, using means, medians, and associated confidence intervals for continuous measures, simple ratios and Clopper-Pearson confidence intervals for binary measures. Kaplan-Meier curves will be used to depict OS. |
Up to 5 years
|
Collaboratori e investigatori
Sponsor
Sponsor
Collaboratori
Collaboratori
Investigatori
Investigatori
- Investigatore principale: Ryan D. Cassaday, MD, Fred Hutch/University of Washington Cancer Consortium
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Neoplasie
- Malattie del sistema immunitario
- Infezioni
- Malattie virali
- Neoplasie per tipo istologico
- Malattie ematologiche
- Infezioni da virus del DNA
- Malattie linfatiche
- Malattie linfoproliferative
- Disturbi immunoproliferativi
- Linfoma non Hodgkin
- Linfoma, cellule B
- Linfoma
- Leucemia, linfoide
- Leucemia
- Infezioni da virus di Epstein-Barr
- Infezioni da Herpesviridae
- Infezioni da virus tumorali
- Leucemia-linfoma linfoblastico a cellule precursori
- Malattie emiche e linfatiche
- Linfoma di Burkitt
- Leucemia-linfoma linfoblastico a cellule T precursore
- Peptidi
- Aminoacidi, peptidi e proteine
- Proteine
- Prodotti chimici organici
- Composti eterociclici
- Composti eterociclici, 2 anelli
- Composti eterociclici, anello fuso
- Tecniche investigative
- Tecniche di laboratorio clinico
- Tecniche e procedure diagnostiche
- Diagnosi
- Idrocarburi
- Idrocarburi, ciclici
- Fattori biologici
- Carboidrati
- Alcaloidi
- Podofillotossina
- Tetraidonaftalene
- Naftalene
- Idrocarburi policiclici aromatici
- Idrocarburi, aromatici
- Composti policiclici
- Glucosidi
- Glicosidi
- Idrolasi
- Enzimi
- Enzimi e coenzimi
- Indoli
- Anticorpi, monoclonali
- Anticorpi
- Immunoglobuline
- Immunoproteine
- Proteine del sangue
- Globuline sieriche
- Globuline
- Incinta
- In gravidanza
- Steroidi
- Composti anelli fusi
- Tecniche di chimica, analitiche
- Analisi dello spettro
- Senape di fosforamide
- Composti di senape di azoto
- Composti di senape
- Idrocarburi, alogenati
- Fosforamidi
- Composti organofosfori
- Peptidi e proteine di segnalazione intercellulare
- Incintadienediols
- Amidoidrolasi
- Vinca Alkaloids
- Alcaloidi di triptamina di secologia
- Alcaloidi indolo
- Indolizidine
- Indolizine
- Antracicline
- Naftaceni
- Aminoglicosidi
- Glicoproteine
- Glicoconiugati
- Anticorpi, monoclonali, derivati da murina
- Daunorubicina
- Fattori stimolanti le colonie
- Fattori di crescita delle cellule ematopoietiche
- Citochine
- Rituximab
- Prednisone
- Ciclofosfamide
- Etoposide
- Doxorubicina
- Vincristina
- Asparaginasi
- Gestione dei campioni
- Spettroscopia di risonanza magnetica
- CT-P10
- Fattore stimolante le colonie di granulociti
- Filgrastim
- Deltacorne
- Prednylidene
- pegfilgrastim
- asparaginasi Erwinia chrysanthemi ricombinante
- fattore stimolante le colonie di granulociti
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- RG1124788
- NCI-2024-09417 (Identificatore di registro: CTRP (Clinical Trial Reporting Program))
- FHIRB0020869 (Altro identificatore: Fred Hutch/University of Washington Cancer Consortium)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .